SPAIN | ACTIS
06/11/2019
Lmite 17 Dic 2020
Oferta Tecnolgica
Ref.
TOIT20191119001
Non-internalizing, linker-less galectin-3 binding protein targeting antibody-drug conjugate for treatment of cancer
An Italian SME specialized in drug discovery has developed and patented a non-internalizing, linker-less antibody-drug conjugate (ADC) targeting galectin-3 binding protein (Gal-3 BP) for treating cancer. This molecule has shown potent therapeutic efficacy combined with good stability and safety profile. The SME is looking for pharmaceutical companies or investors for financial or license agreement to further develop the product in clinical trials.A research cooperation agreement is also foreseen.
Socios

logotipo CEOE Aragnlogotipo ITAINNOVAlogotipo Cmara Toledologotipo FEDAlogotipo UCLM
logotipo FUNDECYT-PCTEX logotipo ADERlogotipo FERlogotipo AINlogotipo UNAV

06/11/2019

Requerimientos: IE 6.0+, FF 1.5+ 1024x768+ | Aviso Legal | Confidencialidad

06/11/2019